EGFR and non-small cell lung carcinoma: Therefore, in the present study, the clinical outcomes of EGFR mutation-positive advanced NSCLC patients treated with first- and second-generation EGFR-TKIs as their first-line treatment were investigated in terms of the EGFR mutation subtypes as well as the agents.